Pay in 4 interest-free payments of $5.02 Learn more
Ships within 48 hours · Estimated delivery Sep 4 - Sep 9
Retatrutide Retatrutide Triple agonist (GLP-1 / GIP / GCG) under investigation in metabolic research
Eligible beneficiaries contribute a $50 monthly copay, making the total out-of-pocket cost dramatically lower than commercial pricing
More Coverage in Less Time Treat up to 4 areas at once at our practice
As of 2026, Eli Lilly has progressed retatrutide into Phase 3 clinical trials, with data expected to inform regulatory submissions in the coming years [10]
[24] [26] Although cross-reactivity with sulfonamide antibiotics appears unlikely, precaution or complete avoidance of nonantibiotic sulfonamides in individuals whose previous reaction was serious and/or life-threatening or in those with multiple drug hypersensitivities may be prudent
US$ 24.41
US$ 22.32
US$ 28.81
US$ 26.59
US$ 27.26
US$ 27.12
US$ 24.10
